AYTU — Aytu BioScience Inc

Aytu BioScience Inc (AYTU) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Joshua R. Disbrow, based in Denver Corporate Center III, Denver, CO, United States, 80237, with about 82 employees. Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Latest reported AYTU revenue for 2025-09-30 was $13.9M. Net income was $2.0M. Revenue was down 79.1% from 2025-06-30 to 2025-09-30. AYTU currently screens at market cap $24.1M.

Use this AYTU page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AYTU quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AYTU SEC filings page. Lician reads the product cache first so this HTML stays unique to Aytu BioScience Inc even when a live quote feed is slow.